Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases

PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 31, 1998

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Diabetes MellitusHypertensionMetabolic DiseaseObesitySleep Apnea Syndrome
Interventions
DRUG

Orlistat

Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.

DRUG

Placebo

Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

collaborator

Roche Pharma AG

INDUSTRY

lead

Jack Yanovski

NIH

NCT00001723 - Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases | Biotech Hunter | Biotech Hunter